The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 22, 2022
Filed:
Sep. 03, 2019
Applicant:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Inventors:
Matthew G. Fury, New York, NY (US);
Israel Lowy, Dobbs Ferry, NY (US);
Assignee:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 47/68 (2017.01); A61K 39/395 (2006.01); A61P 35/04 (2006.01); A61K 51/10 (2006.01); A61N 5/06 (2006.01); C07K 16/30 (2006.01); A61N 5/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 39/395 (2013.01); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 39/39575 (2013.01); A61K 47/6849 (2017.08); A61K 51/1045 (2013.01); A61N 5/06 (2013.01); A61N 5/0603 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2878 (2013.01); C07K 16/3053 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2300/00 (2013.01); A61N 2005/061 (2013.01); A61N 2005/0604 (2013.01); A61N 2005/0605 (2013.01); A61N 2005/0606 (2013.01); A61N 2005/0607 (2013.01); A61N 2005/0608 (2013.01); A61N 2005/0609 (2013.01); A61N 2005/0611 (2013.01); A61N 2005/1098 (2013.01); C07K 2317/21 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract
The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.